UK’s NIHR Government Injects £20 Million into COVID-19 R&D Including Clinical Trials

UK’s NIHR Government Injects £20 Million into COVID-19 R&D Including Clinical Trials

The government, via the National Institute for Health Research (NIHR) of the United Kingdom (UK), announced a £20 million infusion into six research studies focusing on new COVID-19 vaccines in a quest to establish the UK as a major scientific presence in leading the medical response to the novel coronavirus now sweeping the globe. These new research endeavors follow up on other infusions of capital into UK research targeting the novel coronavirus.

This government investment, targeting 2 COVID-19-focused vaccine clinical trials, was announced by Alok Sharma, UK Business Secretary on 23 March 2020. This important capital will inject life into not only vaccine trials but also support the development of vaccine manufacturing at a scale of one-million doses. The other projects center on the repurposing of existing drugs and the development of antibodies that could target the virus as well as risk-based methods to identify the most at risk individuals. The funding supports the vitally important British national health system (NHS) and associated research efforts. Of course, the hope is that these investments will accelerate all of the efforts.

The projects include the following:

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee